Omalizumab in the therapy of pediatric asthma.

CONCLUSION: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant;moreover, the optimal duration of the treatment with omalizumab in children has yet to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding, might open further therapeutic applications. PMID: 29714140 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research